Monograph Details
|
|
Neoplasms
> Cytotoxic antibiotics
|
|
Mitomycin |
| Manufacturer |
|
Various generic manufacturers |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cytotoxic antibiotic. |
| Generic Name |
|
Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol. |
| Indications |
|
Disseminated adenocarcinoma of the stomach or pancreas. |
| Children |
|
Not recommended. |
| Adults |
|
Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments. |
| Contraindications |
|
Thrombocytopenia. Coagulation disorders. Bleeding tendencies. |
| Precautions |
|
Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended. |
| Interactions |
|
Caution with vinca alkaloids, other chemotherapy. |
| Adverse Reactions |
|
Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting. |
| How Supplied |
|
Contact supplier. |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
